Dilraj Grewal, MD, MBBS; Anthony DeFino , 2025-05-08 21:14:00
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Dilraj S. Grewal, MD, FASRS, provides an update on the progress of therapies for noninfectious uveitis.
While some therapies failed trials, others demonstrated promising results, including dazdotuftide (Tarsier Pharma), which reduced inflammation in patients with uveitis without raising IOP in a phase 3 trial.
“We have several exciting therapies that are currently in investigation across the spectrum of oral, injectable intravitreals as well as topicals for our uveitis patients,” Grewal said.
Sources/Disclosures
Collapse
Grewal DS. New therapeutics for non-infectious uveitis in 2025. Presented at: Retina World Congress; May 8-11, 2025; Fort Lauderdale, Florida.
Disclosures:
Grewal reports consulting for Genentech/Roche.
